Niche Precision Diagnostics OfferingProstatype's focus on a prostate‑cancer prognostic test that integrates biomarkers and clinical data creates a specialized clinical utility. That specialization supports durable demand within care pathways, higher switching costs versus general tests, and clearer commercialization focus.

Conservative Capital Structure (no Reported Debt)A healthy equity ratio and lack of reported debt reduce fixed financing burdens and insolvency risk for a small diagnostics firm. This balance sheet position preserves flexibility to raise equity or pursue partnerships without immediate interest costs, aiding multi‑month resilience.

Asset‑light, Partnership Driven Revenue ModelPer‑test revenue and commercialization via lab/partner channels, combined with a very small employee base (6), imply an asset‑light cost structure. This supports scalable volume growth with limited fixed overhead, improving the path to durable margin expansion if adoption increases.

Bears Say

Sustained Operating LossesOngoing negative net income and EBIT show the business has not reached operational profitability. Persistent losses erode equity, limit reinvestment capacity, and imply the company must materially improve margins or revenue to achieve long‑term financial sustainability.

Persistent Negative Free Cash FlowRepeat negative free cash flow and dependence on financing reduce strategic flexibility and increase dilution or refinancing risk. Limited internally generated cash constrains sustained commercialization investments, R&D, and hiring required for durable growth over coming months.

Weak And Declining Revenue GrowthHighly inconsistent and recently steeply negative revenue growth indicates commercialization or market adoption challenges. Without a stabilizing top‑line, margins and cash generation will remain pressured, hampering the company's ability to scale and invest in competitive advantages.

PGO0 FAQ

What was Prostatype Genomics AB’s price range in the past 12 months?

Prostatype Genomics AB lowest stock price was €0.01 and its highest was €0.27 in the past 12 months.

What is Prostatype Genomics AB’s market cap?

Prostatype Genomics AB’s market cap is €9.47M.

When is Prostatype Genomics AB’s upcoming earnings report date?

Prostatype Genomics AB’s upcoming earnings report date is Aug 13, 2026 which is in 176 days.

How were Prostatype Genomics AB’s earnings last quarter?

Currently, no data Available

Is Prostatype Genomics AB overvalued?

According to Wall Street analysts Prostatype Genomics AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Prostatype Genomics AB pay dividends?

Prostatype Genomics AB does not currently pay dividends.

What is Prostatype Genomics AB’s EPS estimate?

Prostatype Genomics AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Prostatype Genomics AB have?

Prostatype Genomics AB has 59,189,320 shares outstanding.

What happened to Prostatype Genomics AB’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Prostatype Genomics AB?

Currently, no hedge funds are holding shares in DE:PGO0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Prostatype Genomics AB

Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The test is based on database containing prostate cancer patients and provides decision support for patients and doctors when making a treatment decision. The company was founded in 2007 and is based in Solna, Sweden.